Design and operation of an automated high-throughput monoclonal antibody facility

Monoclonal antibodies now form a key part of the biochemist’s toolbox, and are important reagents for therapeutic applications. This has resulted in a need for high-throughput production to satisfy the demand from the global community. Manual production involves overwhelming amounts of tissue culture and associated liquid handling steps to achieve high-throughput operation. By contrast, automated systems can readily cope with the numbers required. In this review, we address the development of automated systems, and discuss the pros and cons of their operation.

[1]  J. Reichert,et al.  Development trends for human monoclonal antibody therapeutics , 2010, Nature Reviews Drug Discovery.

[2]  Timothy B. Stockwell,et al.  The Sequence of the Human Genome , 2001, Science.

[3]  B. Lentz,et al.  Polymer-induced membrane fusion: potential mechanism and relation to cell fusion events. , 1994, Chemistry and physics of lipids.

[4]  Valsamo Anagnostou,et al.  Antibody validation. , 2010, BioTechniques.

[5]  J. Wolchok,et al.  Antibody therapy of cancer , 2012, Nature Reviews Cancer.

[6]  Cecilio J. Vidal,et al.  Post-Translational Modifications in Health and Disease , 2011 .

[7]  D. Mccormick.  Sequence the Human Genome , 1986, Bio/Technology.

[8]  Cathy H. Wu,et al.  The Human Proteome Project: Current State and Future Direction , 2011, Molecular & Cellular Proteomics.

[9]  C. James,et al.  Application of automated dried blood spot sampling and LC-MS/MS for pharmacokinetic studies of AMG 517 in rats. , 2011, Bioanalysis.

[10]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[11]  Ario de Marco,et al.  Comparison and critical analysis of robotized technology for monoclonal antibody high‐throughput production , 2011, Biotechnology progress.

[12]  Sam Michael,et al.  A robotic platform for quantitative high-throughput screening. , 2008, Assay and drug development technologies.

[13]  B. Aryal,et al.  Pharmacokinetics of venlafaxine and its major metabolite o-desmethylvenlafaxine in freely moving mice using automated dosing/sampling system , 2012, Indian journal of pharmacology.

[14]  M. Mann,et al.  Proteomic analysis of post-translational modifications , 2003, Nature Biotechnology.

[15]  K. Arnold,et al.  Exclusion of poly(ethylene glycol) from liposome surfaces. , 1990, Biochimica et biophysica acta.

[16]  K. Colwill,et al.  A roadmap to generate renewable protein binders to the human proteome , 2011, Nature Methods.

[17]  Taosheng Chen,et al.  An Automated Approach to Efficiently Reformat a Large Collection of Compounds , 2011, Current chemical genomics.

[18]  H. Bartels,et al.  Automation of wet chemical analysis with AMICA , 1983 .

[19]  Matthew Troutman,et al.  Optimizing ELISAs for precision and robustness using laboratory automation and statistical design of experiments. , 2008, Journal of immunological methods.

[20]  E. Lundberg,et al.  A Genecentric Human Protein Atlas for Expression Profiles Based on Antibodies* , 2008, Molecular & Cellular Proteomics.

[21]  Belinda Bullard,et al.  High throughput production of mouse monoclonal antibodies using antigen microarrays , 2005, Proteomics.